Company facts
- Founded
- 2025
- Headquarters
- Switzerland
About
Glioblastoma (GBM) is the most aggressive and fatal brain cancer, with a median survival of just 15 months. We have developed a dual-action CAR-T cell therapy for GBM, targeting the tumor directly while secreting a CD47-blocker to reprogram macrophages and mount a coordinated immune attack against the tumor. With our…